Patents by Inventor Dennis Klinman
Dennis Klinman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070010470Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: May 11, 2005Publication date: January 11, 2007Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20060094683Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: December 7, 2005Publication date: May 4, 2006Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20060089326Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: December 7, 2005Publication date: April 27, 2006Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman, Alfred Steinberg
-
Publication number: 20060074039Abstract: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.Type: ApplicationFiled: July 31, 2003Publication date: April 6, 2006Inventors: Dennis Klinman, Rainald Zeuner, Daniela Verthelyi, Ihan Gursel, Mayda Gursel
-
Publication number: 20060058251Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.Type: ApplicationFiled: March 6, 2003Publication date: March 16, 2006Applicants: University of Iowa Research Foundation, The US, as Represented by the Secretary, Department of Health and Human Services, Coley Pharmaceutical Group, Inc.Inventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20060003955Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: February 25, 2005Publication date: January 5, 2006Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary Department of Health & Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman, Alfred Steinberg
-
Patent number: 6977245Abstract: D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula: 5?X1X2X3Pu1 Py2 CpG Pu3 Py4 X4X5X6(W)M(G)N-3? wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.Type: GrantFiled: February 6, 2002Date of Patent: December 20, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Dennis Klinman, Daniela Verthelyi, Ken Ishii, James J. Mond, Mayda Gursel
-
Publication number: 20050277609Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: January 7, 2005Publication date: December 15, 2005Applicants: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050277604Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: May 9, 2003Publication date: December 15, 2005Applicants: University of Iowa Research Foundation, The U.S.A., as represented by the Secretary, Department of Health and Human Services, Coley Pharmaceutical Group, Inc.Inventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050267064Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: May 23, 2005Publication date: December 1, 2005Applicants: University of Iowa Research Foundation, United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman
-
Publication number: 20050244380Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: May 11, 2005Publication date: November 3, 2005Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050244379Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: May 11, 2005Publication date: November 3, 2005Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050245477Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: May 11, 2005Publication date: November 3, 2005Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050239736Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 25, 2005Publication date: October 27, 2005Applicants: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050239732Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: October 1, 2004Publication date: October 27, 2005Inventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050233995Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: April 23, 2004Publication date: October 20, 2005Applicants: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050233999Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: October 1, 2004Publication date: October 20, 2005Inventors: Arthur Krieg, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050215500Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: October 22, 2004Publication date: September 29, 2005Applicants: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Arthur Krieg, Joel Kline, Dennis Klinman, Alfred Steinberg
-
Publication number: 20050214355Abstract: Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a Pseudomonas exotoxin, a Diphtheria toxin, and a radionuclide, can be used to dramatically reduce the growth of solid tumors.Type: ApplicationFiled: July 30, 2002Publication date: September 29, 2005Inventors: Dennis Klinman, Ihsan Gursel, Ken Ishii, Koji Kawakami, Bharat Joshi, Raj Puri
-
Publication number: 20050209184Abstract: D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula: 5? X1X2X3Pu1 Py2 CpG Pu3 Py4X4X5X6(W)M(G)N-3? wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response are provided.Type: ApplicationFiled: May 17, 2005Publication date: September 22, 2005Inventors: Dennis Klinman, Daniela Verthelyi, Ken Ishii, James Mond, Mayda Gursel